University of Tennessee Health Science Center/Le Bonheur Children's Hospital, Memphis, TN, USA.
University of Tennessee Health Science Center, Memphis, TN, USA.
J Pediatr Urol. 2022 Dec;18(6):804-811. doi: 10.1016/j.jpurol.2022.03.022. Epub 2022 Apr 11.
Ureteral stents are commonly used during pyeloplasty to ensure drainage and anastomotic healing. Antibiotic prophylaxis is often used due to concerns for urinary tract infection (UTI). Although many surgeons prescribe prophylactic antibiotics following pyeloplasty, practices vary widely due to lack of clear evidence-based guidelines. We hypothesize that the rate of stent UTI does not significantly vary between children who receive antibiotics and those who do not.
We reviewed the medical records of 741 patients undergoing pyeloplasty between January 2010 and July 2018 across seven institutions. Exclusion criteria were: age older than 22 years, no stent placed, externalized stents used, and incomplete records. Surgical approach, age, antibiotic use, stent duration, Foley duration, and urine culture results were recorded. Patients were categorized into two groups, those younger than four years of age and those four years and older as proxy for likely diaper use. Univariate logistic regression was conducted to identify variables associated with UTI. Multivariable backward stepwise logistic regression was used to identify the best model with Akaike information criterion as model selection criteria. The selected model was used to calculate odds ratios and 95% confidence intervals summarizing the association between prophylactic antibiotics and stent UTI while controlling for age, gender, and intra-operative urine cultures.
672 patients were included; 338 received antibiotic prophylaxis and 334 did not. These groups differed in mean age (3.91 vs. 6.91 years, P < .001), mean stent duration (38.5 vs. 35.32 days, P < .001), and surgical approach (53.25% vs. 32.04% open vs. laparoscopic, P < .001). The incidence of stent UTI was low overall (7.59%) and similar in both groups: 31/338 (9.17%) in the prophylaxis group and 20/334 (5.99%) in the non-prophylaxis group (P = .119). Although female gender, likely diaper use, and positive intra-operative urine culture were each associated with significantly higher odds of stent UTI, prophylactic antibiotic use was not associated with significant reduction in stent UTI in any of these groups. Surgical approach, stent duration, and Foley duration were not associated with stent UTI.
Incidence of stent UTI is low overall following pyeloplasty. Prophylactic antibiotics are not associated with lower rates of stent UTI following pyeloplasty even after controlling for risk factors of female gender, likely diaper use, and positive intra-operative urine culture. Routine administration of prophylactic antibiotics after pyeloplasty does not appear to be beneficial, and may be best reserved for those with multiple risk factors for UTI.
肾盂成形术中常使用输尿管支架以确保引流和吻合口愈合。由于担心尿路感染(UTI),常使用抗生素预防。尽管许多外科医生在肾盂成形术后都会开预防性抗生素,但由于缺乏明确的循证指南,实践差异很大。我们假设接受抗生素和未接受抗生素的儿童之间,支架相关 UTI 的发生率没有显著差异。
我们回顾了 2010 年 1 月至 2018 年 7 月在七家机构接受肾盂成形术的 741 名患者的病历。排除标准为:年龄大于 22 岁、未放置支架、使用外置支架和记录不完整。记录手术方法、年龄、抗生素使用、支架持续时间、 Foley 持续时间和尿液培养结果。患者分为两组,年龄小于 4 岁和 4 岁以上的患者(代表可能使用尿布)。采用单变量逻辑回归确定与 UTI 相关的变量。采用多变量向后逐步逻辑回归,以 Akaike 信息准则为模型选择标准,确定最佳模型。使用选定的模型计算优势比和 95%置信区间,以总结预防性抗生素与支架 UTI 之间的关联,同时控制年龄、性别和术中尿液培养。
纳入 672 名患者;338 名接受抗生素预防,334 名未接受。这两组在平均年龄(3.91 岁与 6.91 岁,P<0.001)、平均支架持续时间(38.5 天与 35.32 天,P<0.001)和手术方法(53.25%与 32.04%的开放与腹腔镜,P<0.001)方面存在差异。支架 UTI 的总体发生率较低(7.59%),且两组相似:预防组 31/338(9.17%),非预防组 20/334(5.99%)(P=0.119)。尽管女性、可能使用尿布和术中尿液培养阳性均与支架 UTI 的发生风险显著增加相关,但预防性抗生素使用与任何一组支架 UTI 的发生率均无显著降低相关。手术方法、支架持续时间和 Foley 持续时间与支架 UTI 无关。
肾盂成形术后支架 UTI 的总体发生率较低。即使在控制女性、可能使用尿布和术中尿液培养阳性等危险因素后,预防性抗生素也与肾盂成形术后支架 UTI 发生率降低无关。肾盂成形术后常规使用预防性抗生素似乎没有益处,可能最好保留给那些具有多重 UTI 风险因素的患者。